Positive Clinical Results for Using Myriad's BRACAnalysis...


Myriad Genetics recently announced clinical results showing that its BRACAnalysis CDx test was able to identify patients with HER2-negative metastatic breast cancer who had improved response with Lynparza , AstraZeneca's PARP inhibitor. The results are based on a collaborative effort between Myriad Genetics and AstraZeneca for identification and treatment of patients with metastatic breast cancer and underlying BRCA 1/2 mutations.



from Biotech News